Articles by Dr. Grace Tan
SPONTAN Phase II Data Shows 10-Minute Onset Time, Meets FDA Requirements for Erectile Dysfunction Treatment
SPONTAN Phase II interim results demonstrate 10-minute median onset versus 60 minutes for oral vardenafil, meeting FDA pharmacokinetic requirements.
Purdue Pharma Dissolution Approved: What It Means for Opioid Crisis
Purdue Pharma, the maker of OxyContin, is set to dissolve after a judge approved its criminal sentence. This landmark decision is a significant development in the ongoing legal battles surrounding the opioid crisis.
FDA Approves First Non-Antipsychotic for Dementia Agitation
The FDA has approved the first non-antipsychotic medication for agitation linked to dementia from Alzheimer's disease. This landmark approval provides a much-needed alternative to antipsychotics, which carry significant risks for this patient population.
Local Pharmaceutical Manufacturing South Africa: SAHPRA Policy Impact 2025
This article examines the implications of SAHPRA's 2025 policies on local pharmaceutical manufacturing in South Africa, focusing on drug accessibility and innovation.
HIV Treatment Clinical Trials Africa: Long-Acting Injectables & AMA Pathways
This article delves into HIV treatment clinical trials in Africa, highlighting long-acting injectables and the AMA pathways for enhanced patient care.
Keenova Therapeutics Presents New TERLIVAZ Clinical Data for Hepatorenal Syndrome at Digestive Disease Week 2026
Keenova Therapeutics shares new TERLIVAZ (terlipressin) clinical analysis for hepatorenal syndrome-acute kidney injury at DDW 2026, expanding treatment evidence.
Verified Clinical Trials Partners with Chubb to Enhance Patient Safety and Data Quality in Clinical Research
Verified Clinical Trials and Chubb announce strategic alliance to improve clinical trial participant safety, data quality, and study integrity worldwide.
Genprex Receives Israel Patent for Reqorsa Gene Therapy Combined with PD-1 Antibodies in Cancer Treatment
Genprex secures Israeli patent protection for Reqorsa gene therapy combination with PD-1 antibodies, strengthening intellectual property portfolio for cancer treatment.
Bispecific Antibodies in Hematological Malignancies: Teclistamab, Mosunetuzumab & Epcoritamab FDA Review
This article delves into the FDA review of bispecific antibodies teclistamab, mosunetuzumab, and epcoritamab for hematological malignancies.
TLX597-Tx PSMA Radioligand Therapy Shows Promise in OPTIMAL-PSMA Trial for Early-Stage Prostate Cancer
TLX597-Tx radioligand therapy demonstrates low organ toxicity in OPTIMAL-PSMA trial, potentially enabling dose intensification for prostate cancer treatment.
EirGenix Expands Japan Biosimilar Strategy at CPHI Japan 2026 Amid Regulatory Support
EirGenix leverages Japan's supportive biosimilar regulatory framework and supply chain transformation to strengthen its strategic presence in the Japanese market.
Digital Health Solutions in MEA Oncology: Impact on Treatment Monitoring & Outcomes
Digital health solutions are revolutionizing oncology in the MEA region, improving treatment monitoring and patient outcomes, particularly with therapies like Keytruda.
Biosimilar Oncology Antibodies: EMA Market Dynamics & Healthcare Impact
This article delves into the market dynamics of biosimilar oncology antibodies, focusing on their role in cancer treatment and implications for healthcare systems.
FDA Approval of Elarekibart: Current Status and Market Implications
Elarekibart has received FDA approval for advanced melanoma, signaling a significant advancement in treatment options and potential shifts in the pharmaceutical market.
SFDA Expedited Review Oncology Drugs: What You Need to Know
Learn about the SFDA's expedited review for oncology drugs, including Pembrolizumab, and how it impacts patient access to essential cancer treatments.
Alzheimer's Clinical Trial Failures: Impact on US Market & Investment
This article examines the implications of recent Alzheimer's clinical trial failures on the US market and investment trends, focusing on drugs such as Aducanumab.
Argo Biopharma Doses First Patient in Phase I Trial of siRNA Therapy BW-50218 for TTR-Related Disease
Argo Biopharma begins Phase I clinical trial of BW-50218, an siRNA therapeutic targeting transthyretin protein for rare disease treatment in Australia.
Jyong Biotech Advances Market Access Strategy for Botanical Drug Botreso® and PCP Pipeline
Jyong Biotech (NASDAQ: MENS) updates market access strategies for botanical drugs Botreso® and PCP, establishing competitive advantages in plant-derived therapeutics.
NMPA Conditional Approval Pathway: Accelerating Innovative Oncology Drug Access in China
The NMPA Conditional Approval Pathway is transforming access to innovative oncology drugs such as [Drug Name], expediting their availability for patients in China.
Automation Transforming Eco-Friendly Pharma Packaging
Explore how automation is revolutionizing sustainable pharmaceutical packaging. This article covers innovative systems, solutions, and supplier roles shaping eco-friendly packaging in pharma.